Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Alnylam soars 31% on drug study
Alnylam soars 31% on drug study
Alnylam soars 31% on drug study
Submitted by
admin
on July 16, 2012 - 12:21pm
Source:
Marketwatch
News Tags:
Alnylam
ALN-TTR02
TTR-mediated amyloidosis
Headline:
Alnylam soars 31% on drug study
Do Not Allow Advertisers to Use My Personal information
